LAGUNA HILLS, Calif., March 27, 2013 (GLOBE NEWSWIRE) -- Itonis, Inc. (OTC:ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to provide a status update on Itonis Pharmaceuticals' developments on its over-the-counter homeopathic spray for the treatment of nausea.
The Company previously announced the selection of its U.S.-based manufacturer. Under the leadership of Dr. Hensley, the Company is on target to begin full production of its anti-nausea spray with product sales set to begin by Summer 2013.
"We are very excited that our new anti-nausea product will reach consumers just in time for summer vacation travels. It is always a proud moment when a product cycle matures from the design phase and advances to the point of actual consumer use. Please stay tuned for further production updates in the coming weeks and months ahead," says Dr. Hensley, President of Itonis Pharmaceuticals, and Mark Cheung, CEO of Itonis, Inc.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.